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Abstract | Psoriasis is a chronic, immune-mediated disorder with cutaneous and 
systemic manifestations and substantial negative effects on patient quality of life. 
Psoriasis has a strong genetic basis, still mostly unknown; the majority of the 
identified genes linked to psoriasis belong to the human leukocyte antigens complex 
and others including interleukin 23 and the interleukin 23 receptor axis.Psoriasis 
pathophysiology is characterized by abnormal keratinocyte proliferation and 
immune cell infiltration in the dermis and epidermis involving the innate and 
adaptive immune system, with important roles for dendritic cells and T cells among 
others. Frequent comorbidities are rheumatologic and cardiovascular in nature, in 
particular psoriatic arthritis. Current treatments for psoriasis include topical agents, 
photo-based therapies, traditional systemic drugs, and biologic agents. Treatments 
can be used in combination or as monotherapy. Biologic therapies targeting specific 
disease mediators have become a mainstay in treatment of moderate-to-severe 
disease, whereas advances in the treatment of mild-to-moderate disease have been 
limited. 
 
 
 
 
 
 
 
 
 
 
[H1] Introduction  
Psoriasis is a chronic, immune mediated disorder that mainly affects the skin and 
joints and that has a complex genetic architecture, with an estimated global 
prevalence of 2-3%.(1) Psoriasis is predominantly a skin disease, phenotypes 
including plaque-type psoriasis (further referred to as psoriasis vulgaris), guttate 
psoriasis, inverse psoriasis, pustular psoriasis (including palmoplantar pustulosis, 
acrodermatitis continua of Hallopeau, and generalised pustular psoriasis), 
palmoplantar psoriasis, and erythrodermic psoriasis. Multiple phenotypes may 
occur in the same individual. Psoriasis vulgaris is the most common manifestation, 
(Figure 1).(2) Symptoms shared by all phenotypes can include itching, burning, and 
soreness. The extent of skin involvement is variable. Most types of psoriasis have a 
cyclic evolution, flaring for a few weeks or months, then subsiding for some time or 
even going into a period of remission. 
 
Psoriasis is a systemic, inflammatory disease, in which increased release of pro-
inflammatory cytokines from immune-related cells and chronic activation of the 
innate and adaptive immune system are mechanisms causing long-term damage to 
multiple tissues and organs. Psoriasis has been associated with numerous co-
morbidities, including rheumatologic (psoriatic arthritis [PsA]), cardiovascular, and 
psychiatric complications (Box 1), and has well-described negative effects on 
patient quality of life. (3) (4)  
 
In this Primer, we describe the epidemiology, pathophysiology and diagnosis of 
psoriasis, the available therapeutics and agents in the developmental pipeline and 
the potential of new treatments to positively affect patient quality of life.  
 
[H1] Epidemiology  
[H2] Prevalence and incidence Psoriasis affects over 125 million people 
worldwide (Figure 2). Women and men are affected equally. Psoriasis can manifest 
at any age, but onset usually occurs between 18–39 years of age or between 50–69 
years of age.(5) Age of onset may be affected by genetic and environmental factors. 
Psoriasis is less common in children than adults; the prevalence among children 
ranged from 0% in Taiwan to 2.1% in Italy(5), and the incidence estimate reported 
in the United States was 40.8 per 100,000 person-years.(6) Psoriasis incidence in 
adults varied from 78.9 per 100,000 person-years in the United States to 230 per 
100,000 person-years in Italy.(5)  
 
The incidence of psoriasis appears to be increasing over time. In a retrospective 
cohort of adults, the incidence increased from 50.8 cases per 100,000 population 
between 1970–1974 to 100.5 cases per 100,000 individuals between 1995–
1999.(7) In a retrospective cohort of children with psoriasis, the incidence 
increased from 29.6 to 62.7 cases per 100,000 in the same period.(6) 
 
The National Psoriasis Foundation has defined mild psoriatic skin disease as having 
< 3% body surface area affected, moderate disease as 3–10%, and severe disease as 
> 10%.(8). Additional classifications of psoriasis severity include psoriasis-area-
severity-index (PASI) and physician global assessment (PGA), among others. While 
both BSA and PGA are used in the clinical practice of some authors, PASI is typically 
limited to the clinical trial setting.   
 
[H2] PsA 
Among psoriatic comorbidities, PsA is one of the most frequent, affecting 0.3–1% of 
the global population.(9) Depending on the study, 11%, (10)20.6%(11) or 30%(12) 
of patients with psoriasis are estimated to have concomitant PsA. Males and females 
are affected equally, and peak age of onset is between 35–45 years of age. In most 
patients with psoriasis who also develop PsA, the onset of arthritis occurs 
approximately 10 years after the onset of their skin disease. However, 15% of 
patients develop arthritis before cutaneous manifestations of psoriasis appear. (13) 
There is no direct correlation between the severity of joint and skin manifestations.  
 
[H2] Cardiovascular comorbidities  
Psoriasis has been associated with an increased prevalence of clinical (14) 
atherosclerosis and systemic and vascular inflammation (Figure 3).  
 
Comorbid cardiovascular diseases remain the leading cause of death among patients 
with psoriasis.(15) Large scale, population-based epidemiological studies have 
demonstrated that psoriasis is associated with an increased risk of cardiovascular 
events beyond traditional risk factors and body mass index.(16, 17) Patients with 
severe psoriasis have an approximately 7-fold increased risk of myocardial 
infarction compared to age-, sex-, BMI-, and cardiovascular risk factor-matched 
controls.(17); risk of cardiovascular mortality is increased by 57%.(17) In addition, 
a dose response correlation between severity of psoriasis and odds of having a 
myocardial infarction has been demonstrated and an age-interaction has been 
shown whereby a 30-year-old patient with severe psoriasis has an approximate 2-
fold increase in the risk of experiencing a first myocardial infarction.(17)  
 
However, the association between psoriasis and cardiovascular comorbidities 
remains controversial and not all reports support the mentioned associations. Some 
articles have reported that patients with psoriasis are not at increased risk for 
atherosclerosis, coronary heart disease, stroke, heart failure(18) or ischemic heart 
disease hospitalization.(19) Thus, it has been suggested that such correlation might 
only apply to patients with severe psoriasis.  
 
Furthermore, a higher prevalence of psychosocial distress or psychiatric disorders 
including stigmatization, social discomfort, anxiety and depression has been 
demonstrated in individuals with psoriasis.(20)  
 
[H1] Mechanisms/pathophysiology 
[H2] Genetics 
Psoriasis has a strong genetic component, initially assessed by epidemiologic 
studies involving twins and families (21, 22). Twin studies have found a 
substantially higher (2–3.5-fold) concordance of psoriasis in monozygotic compared 
with dizygotic twins (23), and estimates of heritability (the proportion of variance 
in overall disease liability accounted for by genetic factors) have ranged between 
5090% in populations of European descent.(22, 24) Recurrence rates (disease 
prevalence among relatives compared with the general population) range between 
4–19% in first-degree relatives of individuals with psoriasis(25-27). Even higher 
genetic effects have been reported for PsA, with estimates of heritability between 
80–100% (25, 26) and risk of developing PsA said to be 30–49-fold greater if a first-
degree relative has PsA.(25-28) The role of genetic factors has been confirmed by 
linkage studies  (which measure transmission of alleles through generations) in 
families and genetic association studies (which compare allele frequencies between 
cases and controls).(29, 30) Although over 40 genes associated with psoriasis have 
been identified, they only explain 30% of psoriatic heritability, which may be 
explained by cumulative effects of many genetic variations whose individual effects 
are small, as well as gene-gene and/or gene-environment interactions.. 
 
The genetic landscape of psoriasis is dominated by mutations in the psoriasis 
susceptibility locus 1 (PSORS1), which comprises genes in the human leukocyte 
antigens (HLA) complex (encoding the major histocompatibility complex proteins), 
with smaller contributions from a multitude of other genetic loci (Table 1). Linkage 
and family-based association strategies have enabled important advances in the 
genetic dissection of the associations between HLA genes and psoriasis (31, 32), 
including the differential analysis of cutaneous psoriasis and PsA. (33) The strongest 
HLA-related associations in psoriasis have consistently mapped to HLA-C*06 in 
white (32) and Chinese (34) populations, particularly in patients with early-onset 
and more-severe disease who have a positive family history.(35) However, 
regression analyses have identified at least seven independent HLA genetic 
signatures for psoriasis based on single-nucleotide polymorphism (SNP) typing, 
which have been mapped by imputation to HLA-C, HLA-B, HLA-A and HLA-DRA.(33) 
Notably, amino acid 45 of HLA-B, which maps to the B pocket of the peptide-binding 
groove, discriminates cutaneous psoriasisfrom PsA across a number of different 
HLA-B alleles. (33) Besides the HLA complex, linkage-based strategies have 
identified 17 susceptibility loci,(36-38) although only a few genes have been 
confirmed by subsequent linkage and/or association studies, because of the smaller 
effect sizes of genetic signals of non-HLA genes. Confirmed associations include 
mutations in the PSORS2 region (17q24-q25) spanning the CARD14 gene, (39) 
PSORS4 in the epidermal differentiation complex, (40) PSORS7 on chromosome 1p 
spanning the IL23R locus (41) and PSORS6 on chromosome 19p13 spanning the 
TYK2 locus (42) 
 
As dense single nucleotide polymorphism microarrays and ever-increasing sample 
sizes became available, the new millennium marked a strategic shift from linkage to 
association studies, which are more powerful in the search for common 
susceptibility alleles in psoriasis and other complex genetic disorders.(43) By 2016, 
case-control association studies in population of European and Chinese descent 
have identified 87 psoriasis susceptibility regions, including population-specific and 
shared loci.(44-48) This strategy has also been successful for PsA, revealing allelic 
variation between PsA and cutaneous psoriasis at known susceptibility regions.(49, 
50) Novel PsA loci have also been identified by SNP microarrays, including PTPN22, 
which is not associated with cutaneous psoriasis in the cohort studied.(51) 
 
Whereas SNP-based association strategies are suitable for identifying common but 
low-penetrance variants, traditional and next-generation sequencing techniques 
have been fruitful for identifying rare but highly penetrant alleles.(52) A prime 
example is the identification of the CARD14  gene at the PSORS2 locus.(53) (54) 
Targeted and whole-exome DNA sequencing also had key roles in the identification 
of mutations in AP1S3 (chromosome 2q23) (55) and IL36RN (chromosome 2q13) 
genes, (56-58) which are linked to generalized pustular psoriasis, a highly 
inflammatory subtype psoriasis characterized by systemic inflammation. However, 
a genetic heterogenicity exists, particularly among patients with both generalized 
pustular psoriasis and psoriasis vulgaris.(59) 
 
Unlike the high-penetrance and high-effect-size mutations emerging from the 
sequencing-based studies described above, Ǯinteresting candidateǯ genes, in the 
proximity to loci commonly associated with psoriasis cannot simply be assumed to 
play a causative role. Thus, the identification of biological processes that can explain 
the genetic associations is a major focus of current research in psoriasis and other 
complex genetic disorders. (60) Various methods have been developed to measure 
the overlap between observed genetic signals and corresponding functions and 
pathways. For example, functional enrichment analysis is a method that uses 
statistical tests to identify over-represented subgroups of genes or proteins that 
might be associated with disease phenotypes. One study identified 87 significantly 
enriched functions or pathways, many of which are immune-related, such as 
lymphocyte differentiation and regulation, type I interferon signalling and pattern recognition, and nuclear factor κȾ ȋNF-ȾȌ signalling.(61) In fact, the genetic 
signature uncovered by genome wide association studies in psoriasis revealed genes 
involved in immune regulation.(21) (62)   
 
[H2] Immune response  
Psoriasis is a disorder of both the innate and adaptive immune systems, in which 
keratinocytes, dendritic cells, and T cells have central roles. Psoriasis can be 
triggered by various factors in genetically susceptible individuals, including trauma, 
infection (such as HIV and streptococcal), and medications (such as β-blockers, IFN-
α, and lithium).(2) Many abnormalities have been observed involving antigen 
presentation, activation of NF-B signalling pathways, differentiation of T helper 
(TH) cell populations (especially TH17 cells, the primary source of IL-17) and 
enhanced IL-ͳ7 response, which promotes the hostǯs immune response and 
infiltration of immune cells (Figure 4).  
 
Overlapping pathologic mechanisms may also occur in the development of PsA. Key 
mediators in the disease process include infiltration of TH cells, particularly TH17, 
and overproduction pro-inflammatory cytokines; this inflammatory environment 
leads to excessive bone remodelling. IL-23 and IL-22 stimulate bone formation), 
TNF enhanced bone resorption, and IL-17A stimulates both processes.(63) 
 
[H3] Secreted factors  
In psoriasis pathogenesis, a primary initiation phase that triggers pathologic 
inflammation is followed by a chronic inflammatory phase perpetuated by feedback 
loops and amplification signals. Key disease mediators include anti-microbial 
peptides (AMPs) —cationic proteins and members of the innate immune system 
that assist in protection against bacteria, viruses, fungi and parasites — such as 
cathelicidin (CAMP), pro-inflammatory cytokines and chemokines (for example 
TNF-Ƚ, )L-17, IL-22, and CCL20 (among numerous others)) and angiogenic factors. 
CAMP production is absent in healthy keratinocytes and upregulated during 
processes that cause epithelial damage.(64) Complexes formed by CAMP and self-
nucleic acids can evade recognition and subsequent intracellular degradation by 
dendritic cells, Through this process, a wound healing phenotype can be expressed. 
On the other hand, when CAMP binds to viral DNA IFN -driven anti-viral response is 
triggered. CAMP expression is upregulated during processes that cause epithelial 
damage(64); levels are undetectable in healthy keratinocytes but  uncontrolled in 
psoriatic lesions. This, in the setting of keratinocyte damage and self-nucleotides 
release, triggers pathologic IFN signalling cascades and activation of dendritic cells, 
resulting in uncontrolled inflammation.(64) Expression of AMPs leads to the clinical 
manifestations of psoriasis: for example, acanthosis has been linked to cytokines 
such as IL-22(65) and Auspitz sign (punctate bleeding upon the removal of a scale) 
to angiogenic factors, among others.(66) Mutations involved in pustular variants of 
psoriasis might lead to increased activity of IL-8, a neutrophil chemotactic factor, 
and aggregations of neutrophils.(67) Mutations associated with pustular variants of 
psoriasis might also enhance reactivity of IL-36 and activation of NF-κB.(67) These 
underlying signalling processes are typically self-sustaining, and maintain the 
chronic course of psoriasis until one or multiple critical disease mediators, such as 
TNF or IL-17, are inhibited, leading to a temporary improvement of clinical 
manifestations. Even among patients clear of active psoriatic plaques, clinical 
evaluation of normal-looking skin can unveil abnormal signalling involving key 
inflammatory pathways.(68)  
 
[H3] Cellular mediators 
T cell signalling is essential in understanding the pathogenesis, treatment and 
comorbidities associated with psoriasis. Multiple T cell lineages have been 
described, including TH1, TH2, TH9, TH17, TH22, and regulatory Treg cells.(69) Each T 
cell lineage produces its own signature cytokines and processes signals through a 
set of transcription factors. At the most rudimentary level, TH1 is associated with )FNγ and )L-12, TH17 with IL-23 and IL-17 and TH22 with IL-22, whereas TNF is not 
specific to a single TH cell profile. Although this traditional paradigm of separate T 
cell lineages may predominate, there are exists heterogeneity with secretion of 
factors from multiple different T cell lines and plasticity with switching between T 
cell lineages under certain conditions.(70) 
The role of keratinocytes in psoriasis also extends beyond its association with the 
classic psoriasis histologic phenotype of epidermal hyperplasia and acanthosis 
(increase in the thickness of the stratum spinosum of the epidermis).(65) Although 
the primary physiological function of keratinocytes is the establishment and 
maintenance of the skin barrier, they also produce inflammatory cytokines such as 
TNF, express IL-17 receptors and participate in both the initiation and amplification 
of psoriasis (Figure 4).(71)  
 
Finally, among other innate immune cells, dendritic cells are essential not only as 
professional antigen presenters and cytokine producers, but also as a bridge 
between innate and adaptive immune systems.(72) Plasmacytoid dendritic cells are 
components of the innate immune system circulating in the blood; they can detect 
viral and other antigens and respond by releasing type 1 interferons during the 
initiation phase of inflammation in psoriasis, whereas myeloid dendritic cells 
promote the expansion of specific TH cell populations through production of 
cytokines such as IL-12 and IL-23.  
 
[H1] Diagnosis, screening and prevention 
 
[H2] Cutaneous involvement in psoriasis 
 
The majority of patients with psoriasis initially present with cutaneous involvement, 
with a minority, approximately 15%, experiencing joint symptoms such as swelling 
or pain prior to skin involvement.(13) Several types of skin manifestations 
associated with psoriasis have been described (Figure 1). Although the diagnosis of 
psoriasis vulgaris can often be made based exclusively on clinical signs, further 
investigation including histological examination of a skin biopsy might be helpful in 
diagnosis (Figure 5). Cutaneous disease severity can be rated by measures such as 
the physician global assessment (PGA) (a 0–5 composite score of erythema (redness 
of the skin), induration (thickening or elevation of the skin), and scale, body surface 
area (BSA) (a percentage of body surface area affected by psoriasis with one palm of 
the patient equivalent to 1%) and the psoriasis area and severity index (PASI) (a 0–
72 composite score of erythema, induration and scale, with a multiplier based on the 
total affected body surface area); in both scoring systems higher scores correspond 
to more severe disease.(73) Although absolute PASI score is often used to define 
severity, percentage response rate is often used to define response to treatment. For 
example, PASI 75 indicates the percentage of patients who have achieved a >75% 
reduction in PASI scores from baseline.  
 
Given that psoriasis vulgaris is the most prevalent subtype, we will use this as an 
example to explain characteristic features of skin involvement in psoriasis. Psoriasis 
vulgaris typically manifests as well-circumscribed, symmetric, pink-to-
erythematous, scaly plaques on the scalp, trunk and extremities. Extensor surfaces 
(for example, the elbows, knees, and sacral area, although any area might be 
affected. Psoriatic plaques might exhibit the Auspitz sign (pinpoint bleeding with 
removal of scale) and Koebner phenomenon (appearance of psoriasis at sites of 
trauma; Figure 6), although these signs are not specific for psoriasis. Other features 
can include changes in the nails observed in 50% of patients, such as pitting 
(depressions in the nail plate due to involvement in the proximal nail matrix), 
leukonychia (whitening of the nail plate due to mid-matrix involvement), 
onycholysis (detachment of the nail plate from the nail bed), subungual 
hyperkeratosis (excessive proliferation of keratinocytes in the nail bed), and oil 
drop sign (due to onycholysis involving a more proximal part of the nail)(74) 
(Figure 6)(75) 
 
The differential diagnosis of cutaneous involvement in psoriasis includes various 
disorders (Box 2). Although clinical history and examination might be sufficient to 
distinguish these disorders from psoriasis, other tests such skin biopsy to assess 
histologic findings, anti-nuclear antibodies for autoimmune conditions, flow 
cytometry or T cell clonality studies for abnormal T cell populations, and potassium 
hydroxide test to evaluate for fungal infection might be required to rule out other 
conditions and guide therapeutic decision-making.(76)  
 
[H2] Psoriatic arthritis  
 
PsA is observed in a substantial proportion of patients with psoriasis(77)(Figure 
6C)(75) and usually presents after diagnosis of cutaneous psoriasis. In patients with 
psoriasis, risk factors for developing PsA include severe skin involvement, nail 
lesions, the presence of certain HLA alleles and elevated acute phase proteins and 
matrix metalloproteinase 3 in the serum.(78) (79) (80) PsA presents with 
inflammatory joint pain and erythema over the affected joint and is associated with 
prolonged morning stiffness (>45 minutes), which improves with activity and 
worsens with rest. Although any joint might be affected, the most common sites (in 
order of decreasing frequency) are the feet, hands, knees, ankles, shoulders and 
elbows. Early disease is typically characterized by asymmetric involvement of a few 
joints, with subsequent polyarticular involvement of >5 joints. In addition, axial 
inflammation might limit mobility of spine. Almost 50% of patients develop both 
peripheral and axial disease, whereas only 2–4% experience isolated axial disease. 
Other characteristic features of PsA include dactylitis (inflammation of the whole 
digit) and enthesitis (inflammation at the insertion point of tendons and ligaments 
into bone).(13) Group for Research and Assessment of Psoriasis and Psoriatic 
Arthritis recommends thorough evaluation of multiple PsA domains, including 
peripheral arthritis, axial arthritis, enthesitis, dactylitis and skin and nail disease, 
which might affect disease management.(81) 
 
The diagnosis of PsA has been facilitated by the Classification Criteria for PsA 
(CASPAR) developed through an international study with a large sample size (Box 
3).(82) These criteria are 91% sensitive and 99% specific for disease identification, 
compared with the gold standard ȋphysicianǯs expert opinion based on clinical and 
when necessary radiographic examination). Although such criteria function very 
well in both early and late disease, many cases require rheumatologic expertise for 
definitive diagnosis. A delay in consultation for PsA by only 6 months can result in 
adverse outcomes, including physical disability and peripheral joint erosions, an 
observation that underscores the importance of early diagnosis and treatment of 
PsA.(83)  
 
 Since psoriasis is a common condition, it might co-exist with forms of arthritis other 
than PsA (that is, rheumatoid arthritis, osteoarthritis, and gout, which can be usually 
differentiated by the distribution of the affected joints (Box 4, and Box 5).  
 
[H2] Cardiovascular comorbidities 
Individuals with severe psoriasis should be routinely counselled and screened for 
cardiovascular risk factors. Traditional risk factors include hypertension, 
hyperlipidemia, smoking, diabetes and family history of premature myocardial 
infarction (< 55 years of age). The Framingham Risk Score(84), which is routinely 
used to estimate the 10-year risk for cardiovascular events, is increased by 6% 
when psoriasis is present(85). The 2013 American College of Cardiology and 
American Heart Association guidelines for cardiovascular risk screening do not 
consider psoriasis as a risk(86); however, the European Society of Cardiology 
guidelines note that the increased risk of CV disease observed in patients with 
psoriasis.(87) Furthermore, the U.S.-based Adult Treatment Panel of the National 
Cholesterol Education Program(88) state that inflammatory diseases might be 
considered emerging risk factors, and warrant earlier and more-frequent screening. 
Thus, age appropriate normal screening algorithm recommendations for  
cardiovascular risk factors should be followed after a diagnosis of psoriasis, 
including monitoring resting blood pressure, measurement of the body mass index 
to assess for obesity and cholesterol and glucose serum concentration. After 
diagnosis such tests should be done every five years between 18–40 years of age, 
and then annually. Patients with psoriasis with body surface area exceeding 10% 
should be educated of their heightened risk and might require more-regular 
cardiovascular risk screening.  
 
No guidelines endorse screening for subclinical coronary artery disease. Nevertheless, emerging data suggest that patients with psoriasis who have ≥ʹ 
cardiovascular risk factors might benefit from non-invasive imaging exams to assess 
coronary atherosclerosis burden, such as CT assessment of coronary calcification or 
carotid intimal medial thickness measurement with ultrasonography.  If 
atherosclerosis is suspected, dyslipidemia therapy, including lifestyle changes and 
lipid-lowering agents, might be recommended. Finally, despite accumulating 
evidence that aggressive treatment with anti-TNF biologic agents of psoriasis leads 
to improved surrogate markers for cardiovascular disease such as intima medial 
thickness and vascular inflammation (89) (90) and reduced risk of myocardial 
infarction (14, 91); Randomized clinical trials to confirm these associations are still 
ongoing.(92) (93)  
 
[H1] Management  
The treatment approach for psoriasis depends on multiple factors. The body areas 
involved determine the formulation and dose of the topical treatments. Selection of 
an appropriate therapy is also substantially influenced by the presence of 
comorbidities. In patients with PsA, systemic treatments with, methotrexate or 
biological agents that target both the skin and joints are the most appropriate 
therapies. Concomitant conditions such as HIV, hepatitis B or hepatitis C infection; 
alcoholism; cardiovascular disease or a history of malignancy also influence the 
choice of therapies. Age is another factor to be considered, as some treatments (for 
example, methotrexate) are excreted less efficiently in elderly patients than in 
younger patients, and certain treatments (for example, acitretin) are not safe for use 
in children or women of childbearing age who have a child wish because of their 
teratogenic effects. Recent management guidelines with useful treatment algorithms 
exist in the United States(94) and Europe.(95) 
 
[H2] Topical therapy 
For patients with mild disease (<10% body surface area) and without PsA, topical 
therapy is usually adequate. Historically, dithranol  (also known as anthralin),which 
induce keratinocyte apoptosis, and tars, which reduce IL-15 production and nitric 
oxide synthase activity, were the only treatments available.(96, 97)  
 
Although these treatments are still used, corticosteroids are the mainstay of topical 
psoriasis therapy nowadays. Many different formulations exist.  Solutions, foams, 
sprays, shampoos and gels are prescribed for the scalp, whereas ointments or 
creams are typically used for the face, torso and extremities. Even corticosteroid-
impregnated patches. Steroid-sensitive sites, such as the face and intertriginous 
areas, typically require lower-potency topical corticosteroids or steroid-sparing 
agents, (medications given in addition to or instead of steroid therapy to decrease 
the amount of steroid required) — such as topical vitamin D or its analogues or 
topical calcineurin inhibitors — to minimize adverse effects. More-potent 
corticosteroids can be used for areas of thicker skin, such as the palms, soles, elbows 
and knees. Adverse effects associated with topical corticosteroid use includes 
cutaneous atrophy and and dyspigmentation. 
  
Several topical vitamin D analogues (for example, calcitriol, calcipotriene, tacalcitol 
and maxacalcitol) are approved for psoriasis used as monotherapy or combination 
with corticosteroids and act through immune modulation and normalization of 
keratinocyte maturation. Although these agents are less effective than 
corticosteroids, their adverse effect profile is favorable.(98) Topical retinoids, which 
normalize keratinocyte differentiation and supress the immune response, are 
effective but irritating, and therefore are most often used in combination with 
topical corticosteroids.(99) Topical calcineurin inhibitors, although not approved 
for the treatment of psoriasis, are also widely used in managing psoriasis in steroid-
sensitive areas, owing to their suppression of T cell activation and 
proliferation.(100) 
 
[H2] Phototherapy 
For patients with moderate-to-severe disease, typically characterized by BSA >10%,  
and without PsA, phototherapy can be an effective option when topical application 
to a large area is impractical. Phototherapy acts through multiple mechanisms: 
inducing apoptosis of inflammatory cells (such as antigen presenting cells), 
increasing production of the anti-inflammatory cytokine IL-10 and stimulating TH1 
switching, TH17 suppression and TH2 and Treg activation. (101) Broadband 
ultraviolet B (UVB) radiation has been used since the 1920.(102) It has not been 
associated with an increase in skin cancers(103), likely because the spectrum of 
light used does not include the most carcinogenic short wavelengths found in 
sunlight, and phototherapy dose is gradually increased to limit burns. In addition, 
the most skin cancer-prone areas such as the face are usually protected during 
phototherapy. Narrowband UVB, which includes only the most effective spectrum of 
light wavelengths for the treatment of psoriasis, has gained popularity and largely 
replaced broadband UVB. Both broadband and narrowband UVB are administered 
2-3 times per week(103). Proximity to a phototherapy center used to be a limiting 
factor, but home phototherapy units have become a popular alternative to in-office 
treatments and have demonstrated comparable efficacy.(104) Considerable 
insurance and co-pay costs, photosensitivity, or use of photosensitizing medications, 
are reasons why patients might be reluctant to use phototherapy. 
 
Psoralen combined with UVA (PUVA) treatment is a regimen in which 8-
methoxsalen is administered orally followed by exposure to UVA light 75–120 
minutes later. Although still in use, particularly in patients with skin types with 
lower risk of developing skin cancers, this treatment is less frequently prescribed 
because of its photocarcinogenic effects and association with cutaneous squamous 
cell carcinoma and malignant melanoma.(105),(106) 
 
[H2] Systemic therapy 
For patients with moderate-to-severe psoriasis (>10% BSA), both phototherapy and 
systemic therapy (oral or injectable therapies) may be prescribed, but patients often 
prefer systemic therapy over phototherapy. Systemic therapy might be appropriate 
even for patients with <10% BSA, especially when the face, scalp, palms or soles are 
affected, which can be debilitating or when PsA is also present.(107)  
 
[H3] Methotrexate 
Administered orally or intramuscularly, methotrexate is the oldest systemic therapy 
for psoriasis and is widely used owing to its low cost. As an anti-inflammatory agent, 
methotrexate inhibits the enzyme 5-aminoimidazole-4-carboxamide ribonucleotide  
transformylase, leading to downstream increases in adenosine which leads to 
reduced tumor necrosis factor, nuclear factor NF-kappa-B p105 subunit, and 
transcription factor p65 expression.(108, 109) Key inflammatory cytokines and 
chemokines, including IL-17, IL-23, CCL20 and IL-22, are down-regulated by 
methotrexate. Low-dose methotrexate treatment might also be associated with 
reduced risk of cardiovascular disease, and has been shown to lower the expression 
of atherogenic genes in lesional psoriatic skin.(110)  
 
Methotrexate is teratogenic and therefore contraindicated during pregnancy. The 
most common life-threatening adverse effect associated with methotrexate is bone 
marrow toxicity; pancytopenia or death was reported in 1.4% of patients with 
rheumatoid arthritis receiving low-dose methotrexate and identified risk factors 
included elevated blood urea nitrogen and creatinine, lowered serum albumin, 
infection, drug-drug interactions and advanced age.(111) Because methotrexate 
interacts with numerous medications, a thorough medication history is essential, 
and patients must be warned to seek advice from their doctor before starting any 
other new medications while on methotrexate. For example, the combination of 
methotrexate with antibiotics such as trimethoprim-sulfamethoxazole might 
substantially increases drug toxicity leading to pancytopenia and potentially 
death.(112) Another serious side effect of methotrexate is the development of 
cirrhosis. In one study, hepatic fibrosis was observed in patients with psoriasis who 
were treated with methotrexate; 14 out of 15 of those were obese, 7 out of 7 had 
diabetes, and 9 out of 9 had excessive alcohol intake (exceeding 30 grams).(113) 
Risk factors for methotrexate-induced hepatic toxicity include the persistently 
abnormal liver function tests, a history of chronic hepatitis B or hepatitis C, 
hyperlipidemia, diabetes, and lack of folate supplementation.(114) Oral folic acid 
supplementation can prevent some methotrexate side effects, such as nausea and 
macrocytic anemia.  
 
Routine monitoring during methotrexate therapy includes complete blood count as 
well as liver and renal function tests, both at baseline (before the start of the 
treatment) and at regular follow-up intervals. Monitoring for hepatotoxicity is 
controversial; some guidelines recommend liver biopsies or enzymatic testing in at-
risk patients.(114) (115) 
 
[H3] Acitretin. 
Acitretin is an oral retinoid that reduces the activity of TH1 and TH17 cells and 
normalizes keratinocyte differentiation; it is particularly effective in palmoplantar 
psoriasis.(116) It is modestly effective as monotherapy, but is commonly used in 
combination with phototherapy; this combination results in greater and rapid 
improvement in psoriasis compared with phototherapy or acitretin alone.(117, 118) 
Like methotrexate, acitretin is teratogenic and is typically avoided in women of 
childbearing age, as its teratogenic effect prolongs over the  years because the drug 
is stored in the adipose tissue. Periodic monitoring of blood parameters is done, 
owing to the risk of hyperlipidemia, especially hypertriglyceridemia, and liver 
toxicity. Mucocutaneous side effects, including hair loss, cheilitis (inflammation of 
the lips), dry and sticky skin, pyogenic granulomas and thinning of the nail plates, 
are common and often dose-limiting.(119)  
 
[H3] Cyclosporine 
Cyclosporine is one of the most effective therapies for psoriasis by inhibiting T cell 
activity. After forming a complex with cyclophillin, cyclosporine inhibits calcineurin, 
a phosphatase that activates three nuclear factor of activated T cells isoforms 
(NFAT1, NFAT2, and NFAT4). NFAT is a transcription factor that promotes the 
expression of IL-2, a key pro-inflammatory cytokine.(120) The use of cyclosporine is 
limited by its adverse effects, particularly nephrotoxicity, and numerous drug-drug 
interactions. All patients show evidence of nephrosclerosis on kidney biopsies 
within two years of starting cyclosporine treatment.(121) Thus, most guidelines 
limit the use of cyclosporine to one to two years.(107) Other adverse effects include 
hypertension, hypomagnesemia, hyperkalemia, hyperlipidemia, hypertrichosis and 
increased risk of lymphoma and squamous cell carcinoma with long-term use. 
Frequent monitoring, particularly of serum creatinine levels and blood pressure, is 
essential. 
 
[H3] Apremilast 
Apremilast is a phosphodiesterase-4 inhibitor that limits the degradation of cAMP, 
reduces nitric oxide synthase, TNF-Ƚ, and )L-23 and increases IL-10 levels.(122) It 
was approved as an oral treatment for psoriasis by the United States Food and Drug 
Administration in 2014 and by the European Medicines Agency in 2015. The main 
barrier to its use is insurance coverage, as apremilast is more costly than many of 
the other available oral agents, although it is still substantially less expensive than 
the biologics (see below). Adverse effects include nausea, weight loss and diarrhea, 
which usually occur within the first 15 days after the start of treatment, and in most 
instances, lasts up to 15 days, but in some patients can persist longer.(123) 
Apremilast efficacy is lower than that of many biologic therapies, with 33% of 
patients achieving PASI 75 by week 16 of therapy.(124) However, because it is 
administered orally and has not been associated with an increased risk of infections 
or malignancy, its use has been growing in the United States. 
 
[H3] Fumarates 
Oral fumarates are approved in Germany for the treatment of moderate-to-severe 
psoriasis and are used as an off-label treatment for psoriasis in other 
countries.(125) Believed to down regulate TNF-Ƚ and interleukin 12 and 23 
production,(126), fumarates have demonstrated greater improvement in PASI 
scores than placebo although the comparative efficacy of fumarates and 
methotrexate remains unclear. Common adverse effects include gastrointestinal 
disturbances, flushing, eosinophilia and proteinuria; further characterization of 
their long-term safety profiles is needed.  
 
[H3] Biologic therapies 
A biologic medication should be considered as first-line therapy for moderate-to-
severe disease with significant quality of life impacts, or if there is concomitant PsA; 
biologics should be considered in other cases of moderate-to severe-disease when a 
traditional systemic therapy fails to achieve disease control, or when a patient is 
unable to tolerate the traditional systemic due to side effects. Eight injectable 
biologic therapies are currently approved for moderate-to-severe psoriasis or PsA 
(Table 1), and several other agents, including some targeting IL-23, are in various 
stages of the developmental and approval process. Patient sex(127), BMI, C-reactive 
protein levels (as a marker for inflammation), prior use of biologic therapies and 
concomitant hepatitis B or hepatitis C might affect the response to and selection of 
biologic therapy. TNF-blockers have been particularly effective in patients with 
concomitant PsA.(128)  
 Several anti-TNF agents, that either bind TNF-Ƚ thereby inhibiting receptor binding 
or block TNF receptor activation, are available to manage psoriasis and PsA (Table 
2). In addition, evidence from registry studies showing that anti-TNF agents are 
protective against cardiovascular disease, supports their use, particularly in 
individuals at high risk of cardiovascular events.(91) (129) Other biological agents 
might also provide cardiovascular protection, but there is no clear evidence yet.  
Anti-TNF agents have safety profiles different from those of traditional systemic 
agents and are considered safe during pregnancy.(130) Anti-TNF agents have been 
associated with an increase in infections and certain malignancies, particularly 
cutaneous squamous cell carcinoma(131), whereas these correlations have not been 
observed with ustekinumab or any of the IL-17 blockers.(132) Paradoxical 
worsening of psoriasis has been reported as an adverse effect of anti-TNF agents 
and often resolves with treatment discontinuation.(133) Patients treated with 
biologics agents have an increased risk of developing tuberculosis, and annual 
tuberculosis screening has therefore been recommended. (134)  
 
Ustekinumab (IL-12 and IL-23 specific antibody), secukinumab (anti IL-17A 
antibody) and ixekizumab (anti IL-17A antibody) have been approved for the 
treatment of PsA. (135), (136), (137) Early data on brodalumab, have been 
favorable; (138) however, before potential approval, further evaluation of the 
possible association between suicidal ideation and brodalumab is required and 
ongoing. IL-17 blockers have been associated with the development of candida 
infections, which are easy to treat, and suicidal ideation for brodalumab .(139), 
(140) (141) Ustekinumab and IL-17 blockers can be used safely in patients with 
heart failure and personal or family history of demyelinating diseases, unlike TNF 
blockers, which could cause the development of worsening of advanced congestive 
heart failure and multiple sclerosis .(142)  
 
Head-to-head comparisons of biologics are limited in number. Ustekinumab was 
shown to be more effective than entanercept(143) but less effective than 
secukinumab(144) for cutaneous disease; secukinumab was more effective than 
adalimumab for PsA.(145) The development of anti-drug antibodies and the 
associated reduced efficacy of biologics remain  important concerns.(146) The 
potentially protective role of biologics-methotrexate combination therapies in 
limiting the emergence of anti-drug antibodies in psoriasis needs further evaluation. 
Finally, biosimilars are now approved in Europe, Canada, the United States, and 
Korea and etanercept biosimilar is approved in Europe. Infliximab and etanercept 
biosimilars seem to demonstrate similar efficacy to the original agent and will likely 
reduce the cost of biologics and improve patient access to these medications. (147) 
(148)  
 
[H1] Quality of life  
 
Psoriasis often has profound effects on patient quality of life (QoL).(149) Individuals 
with psoriasis have higher rates of depression, anxiety, suicidal ideation, and 
experience feelings of shame, anger and worry more frequently and/or severely  
than the general population.(20). The degree to which psoriasis affects QoL depends on both the individual patientǯs outlook and personality and the severity of the 
symptoms, which account for 80% of the disease burden. In addition, psoriasis 
severity and age of onset are inversely correlated with QoL and directly associated 
with greater risk of depression and social stigmatization.(150) Furthermore, 
psoriasis influences pivotal life decisions, such as choice of partner, career and 
residence. (151) The lives of the patientsǯ family members or partners might also be 
widely disrupted, which should be taken into account when evaluating overall 
disease burden.(152)  
 
[H2] Measurement 
Quantifying the effect of psoriasis on QoL is essential, as it informs therapeutic 
decisions (including decisions on therapy initiations and treatment goals), 
highlights the aspects of the disease that are most important to the patient and helps 
assess and communicate patient satisfaction. Psoriasis registries also routinely 
record QoL data.(153) Among the several tools measuring QoL in patients with 
psoriasis (Box 6), the Dermatology Life Quality Index is the most widely used. (154) 
(155) EuroQoL 5 Dimension Health Questionnaire, a general health measure, was 
used to compare the burden of psoriasis with that of other conditions and to 
measure the cost effectiveness of novel therapies. The study has demonstrated that 
the negative effect of psoriasis is equal to that of other severe systemic chronic 
diseases.(156)  
 
[H2] Effect of treatment on QOL 
Treatment with biologic agents can substantially improve the disease course and 
QoL sustained over years, although high baseline Dermatology Life Quality Index 
scores might portend treatment discontinuation.(157) Cyclosporine and 
methotrexate improve QoL to a lesser extent than biologic agents do, and 
educational interventions have demonstrated limited effect on QoL.(158, 159) 
Evaluating the effect of psoriasis on patient QoL is essential when discussing 
therapeutic options and allocating healthcare funding, as QoL impairment is 
associated with poor treatment adherence and clinical outcomes. Thus, by 
addressing patient QoL, we might enhance therapeutic success and ultimately 
improve patient care.  
 
[H1] Outlook 
 
Despite advances in the genetic and mechanistic understanding of psoriasis and 
developments in clinical care and treatment modalities, gaps in our knowledge and 
management of this complex, multifactorial disease remain.(160) A 
multidisciplinary approach involving patients, dermatologists, rheumatologists, 
cardiologists, geneticists, pharmacologists, immunologists, and researchers in all 
these fields is necessary to further elucidate the immunopathogenesis of psoriasis 
and continue to develop novel treatments to improve patient QoL (Table 3).  
 
Our understanding of psoriatic comorbidities, such as cardiovascular disease, 
requires further investigation. It is not yet known whether controlling inflammation 
in early psoriasis decreases the risk of PsA development(161) (162) (163), or 
reducing immune activation with biological and oral agents such as methotrexate 
can mitigate cardiovascular morbidity and mortality.(164) Large-scale, innovative 
studies, designed in cooperation with regulatory agencies, are necessary to answer 
these clinically meaningful questions.(161)  
 
[H2] Genetics  
Despite providing remarkable insights into disease pathogenesis, genetic studies of 
psoriasis and other autoimmune disorders pose several challenges. In addition to 
the modest odds ratios associated with most susceptibility loci, approximately 90% 
of these genetic variations do not appear to encode changes in protein structure, but 
rather in gene regulation (transcription level, splicing and mRNA stability).(60) 
Moving forward, the translation of disease-associated genetic variation into biologic 
effects will require innovative use of available resources to decipher the complex 
relationship between the landscapes of chromatin structure and gene regulation 
and the underlying genetic variation.  
 
Mapping of the psoriatic genome is currently underway in a study headed by the 
International Psoriasis Council and upon completion will enable susceptibility gene 
characterization beyond the ~50 known disease loci.(165) Similarly, new 
technologies (such as next generation sequencing), genomic mechanisms (such as 
copy number variation) and epigenetics are being applied to psoriasis and PsA to 
gain a deeper knowledge of their genetic bases.(166) A new taxonomy for psoriasis 
based on molecular targets might also be able to guide treatment decisions.(167) 
The responses to treatment of the different disease endotypes (disease subtype with 
a distinct functional mechanism) are being mapped to create pathobiological 
algorithms for a personalized approach to psoriasis that minimizes treatment 
toxicity and maximizes clinical response and cost efficacy.(168) (169)  
 
[H2] Biomarkers 
Currently no biomarkers are available to evaluate disease prognosis or treatment 
response for patients with psoriasis or PsA. The Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology have 
prioritized the prospective identification and validation of a PsA biomarker through 
the Psoriatic Arthritis Biomarkers for Joint Damage (PsA BioDam) effort.(170) (171) 
Flow cytometry, proteomics, and molecular signalling techniques are being applied 
to identify potential biomarkers with adequate sensitivity and specificity.(172) The 
ability to predict the likelihood that patients with PsA will develop joint destruction 
and to identify which patients with psoriasis will develop PsA will allow early and 
aggressive interventions to slow or prevent debilitating disease outcomes.  
 
[H2] Management 
From a healthcare standpoint, discrepancies between treatment guidelines and 
clinical practice should be corrected, including the large number of patients with 
moderate-to-severe cutaneous disease who receive either no treatment or only 
topical monotherapy(173) because of multiple factors including high treatment 
costs. The introduction of infliximab biosimilars in Europe and Canada has led to a 
price reduction of infliximab by up to 33%. In addition, the transition of biologic 
production from batch-based to a more-sophisticated continuous process with 
greater implementation of single-use technologies has the potential to reduce costs 
without sacrificing product quality.(174) The use of biosimilars and manufacturing 
innovation might reduce health care expenditures and undertreatment rates by 
ultimately passing these savings on to the community. Furthermore, the 
development of outcome measures for clinical practice, which address the needs of 
all stakeholders (patients, health care providers, payers, drug developers, and policy  
regulators) is crucial in improving the quality of care and encouraging further drug 
development for psoriasis and PsA.(175)  
 
 [H2] New treatment targets 
A growing understanding of psoriasis pathophysiology has led to the development 
of several novel topical, systemic and biologic agents, now in various stages of 
approval (Table 2).(176) (177) As chronic treatment with topical agents is the most 
common form of treatment in patients with mild-to-moderate disease, further 
exploration of new targets for topical formulations and innovative delivery systems 
with favorable side effect profiles that facilitate treatment outcomes is 
warranted.(178) Although new biologic agents provide exciting therapeutic options 
for individuals with moderate-to-severe disease, key limitations of these drugs 
include primary and secondary treatment failures and challenging risk-benefit 
analysis.  
 
Possible solutions are targeting of differentially expressed genes and more specific disease mechanisms termed ǯpsoriasis response elementsǯ using sophisticated 
methods like decoy oligonucleotide therapy (selective inhibition of the expression of 
specific genes).(179) (180) (62) Gene expression profiling of lesional skin has 
enabled the definition of differentially expressed genes characteristic of psoriasis 
and subsequent identification of the upstream psoriasis response elements, genomic 
sequences thought to have a regulatory role in disease development. Isolation of 
these sequences might lead to the development of novel decoy oligonucleotides 
(ODNs) that can recognize and bind transcription factors central to psoriasis.(62) 
Such efforts have demonstrated the ability of ODNs to inhibit the onset and reverse 
established psoriatic lesions in psoriatic mouse models.(181)  
 
Current and emerging treatments focus primarily on targeting key mediators 
involved in the chronic phase of psoriasis. Although psoriasis has been generally 
considered a primarily TH1- IFN-γ driven disorder, this pathway might be more 
essential in the initiation phase of the disease.(182) IFN-γ inhibition has not shown 
substantial clinical benefit.(183) Thus, the TH1 axis might be more critical in the 
pathogenic mechanisms of psoriasis as a bridge between the innate and adaptive 
immune responses. The TH17 axis, with its signature cytokines IL-17 and IL-23, has 
emerged as a key driver of the chronic disease process and has become a focus of 
drug development, as agents targeting this pathway have achieved improved clinical 
outcomes. Table 2 lists some of the biological agents currently being assessed. 
Selective IL-23 inhibition (tildrakizumab, guselkumab and risankizumab) (184) and 
combined IL-12 and IL-23 inhibition (ustekinumab, Table 1)(185) produces 
substantial beneficial responses of skin and joints in psoriasis. The TH22–IL-22 axis 
is also an important mediator of the psoriatic phenotype, and therefore could be a 
potential therapeutic target. However, phase I investigation of an IL-22 inhibitor 
(fezakinumab) was terminated early.(186) Although current drug development 
specifically targeting the innate immune system is less advanced, mediators such as 
CAMP are thought to be essential in the pathogenesis of psoriasis.(64)(Figure 4).  
 
As the molecular and genetic pathological mechanisms of psoriasis continue to be 
unravelled, additional therapeutic targets will be developed, perhaps on an 
individualized basis.  
  
Box 1 | Psoriasis associated comorbidities   Psoriatic arthritis  Autoimmune disease  Cardiovascular disease  Obesity  Metabolic syndrome  Chronic obstructive pulmonary disease  Sleep apneaLiver disease   Psychiatric illness 
Addictive behaviour: smoking and alcohol abuse 
  
Box 2 | Differential diagnosis of psoriasis vulgaris. 
- Inflammatory disorders: atopic dermatitis, lichen planus, nummular eczema, 
pityriasis rubra pilaris, pityriasis lichenoides chronica, lupus erythematosus, 
sarcoidosis, pityriasis rosea and seborrheic dermatitis 
- Reactive processes: allergic contact dermatitis, lichen simplex chronicus, 
drug hypersensitivity reaction and erythema annulare centrifugum 
- Infectious disorders: tinea, syphilis and crusted scabies  
- Neoplastic processes: mycosis fungoides (a cutaneous T cell lymphoma), and 
extramammary Paget disease  
Box 3 | CASPAR criteria for the diagnosis of PsA. 
- Evidence of inflammatory articular disease, namely arthritis, spondylitis or 
enthesitis and at least 3 points from the following categories: 
o Current psoriasis (2 points), personal history or family history (first 
or second degree relative) of psoriasis (1 point) 
o Current or history of dactylitis (1 point) 
o Radiographic evidence of juxtaarticular new-bone formation (1 point)  
o Rheumatoid factor negative (1 point) 
o Current nail dystrophy, including pitting, onycholysis, and 
hyperkeratosis (1 point) 
  
Box 4| Differential diagnosis of psoriatic arthritis  Rheumatoid arthritis typically affects the proximal small joints of the hands 
and feet symmetrically, whereas psoriatic arthritis (PsA) more commonly 
affects the distal joints in an asymmetric distribution.   Osteoarthritis affects the distal interphalangeal joints, but its clinical 
presentation is characterized by bony Heberden nodes, which are distinct 
from the soft tissue joint swelling in PsA.   Gout can cause a diagnostic dilemma as both gout and PsA can affect the toes 
and the swollen digits in gout can mimick dactylitis. In these cases, joint 
aspiration and microscopic detection of crystals are helpful diagnostic 
tools.(13) 
  
Box 5| Early screening of psoriatic arthritis  
To facilitate early recognition of psoriatic arthritis (PsA), new screening 
instruments are being explored for non-experts, in particular patient questionnaires 
using lay definitions of inflammatory musculoskeletal disease (187).(188) Several 
instruments, including the Psoriasis Epidemiology Screening Tool, Psoriatic 
Arthritis Screening Evaluation and Psoriatic arthritis screening questionnaire, are 
validated for use among patients with psoriasis. However, sensitivity and specificity 
of these tools vary between different healthcare centers. An updated version of 
Toronto Psoriatic Arthritis Screen, Toronto Psoriatic Arthritis Screen 2, has been 
developed and validated; it was found to be highly sensitive and specific and might 
even serve to screen for PsA both in patients with psoriasis and in the general 
population.(189)  
 
 
  
Box 6 | Questionnaires used to measure the effects of psoriasis on patient quality of 
life  
 
[H1] Psoriasis-specific questionnaires(190)  Psoriasis Disability Index   Impact of Psoriasis Questionnaire (IPSO)  Psoriasis Index of Quality of Life (PsoriQol)   PsoDisk  Psoriasis Life Stress Inventory  Simplified Psoriasis Index (SPI)  Psoriasis itch visual analogue scale (191)   Psoriasis symptom inventory.(192) 
 
[H1] Dermatology-specific questionnaries(190)  Dermatology Life Quality Index (DLQI)  Skindex (versions 16, 17, 29)  
 
[H1] General health measures(190, 193)  Short Form 36 (SF-36)   General Health Questionnaire (GHQ)  World Health Organization Quality of Life (WHOQOL)   EuroQoL 5 Dimensions (EQ-5D)  Pictorial Representation of Illness and Self Measure (PRISM) 
 
[H1] Children-specific questionnaires  Childrenǯs Dermatology Life Quality )ndex (CDLQI)(194) 
 
[H1] Family-oriented questionnaires (195, 196)  Psoriasis Family Impact (PFI)  Family Dermatology Life Quality Index (FDLQI)  Family Reported Outcome Measure (FROM-16)   
Figure 1 | Skin manifestations of psoriasis.  
A. Psoriasis vulgaris is the most common type and is characterized by well-defined 
areas of erythematous and indurated plaques with overlying silvery scale; knees, 
elbows, scalp and trunk are the most commonly affected skin areas. B. Guttate 
psoriasis, the second-most common type of psoriasis, is characterized by small, tear-
shaped papules, often starts in childhood or young adulthood, and can be triggered 
by an infection such as streptococcal pharyngitis. C. Inverse psoriasis is 
characterized by erythematous plaques in the body folds, and due to increased 
moisture in these area often lack scale. Many individuals with inverse psoriasis also 
experience other subtypes of psoriasis simultaneously. D. Pustular psoriasis is 
characterized by sterile pustules on an erythematous base. It is primarily seen in 
adults, usually presents on the hands and feet, and tends to evolve through a cycle, 
with erythema followed by the formation of pustules and scaling. Appearance in 
pregnancy is termed impetigo herpetiformis and may be related to hypocalcemia E. 
Erythrodermic psoriasis is a severe form of psoriasis that can be life-threatening. It 
leads to widespread erythema over at least 90% of the body, which can cause severe 
itching and pain, and can be associated with desquamation of the skin in sheets. It 
affects about 3% of individuals with psoriasis, and generally occurs in patients with 
unstable psoriasis vulgaris. 
 
 
 
  
Figure 2 |Global prevalence of psoriasis. A systematic review of international, 
population-based studies demonstrated a global prevalence of psoriasis in adults 
ranging from 2.2% in the United States to 8.5% in Norway.(5) A study that analyzed 
22 population-based surveys, case-control studies and reviews from around the 
world found a weak positive correlation between higher latitude and greater 
psoriasis prevalence possibly due to level of UV exposure.(197) The lowest 
prevalence rates were observed in Latin American Indians(198), native 
Americans(199), and in African and Asian countries whereas the highest rates were 
reported in Europe. Even within Asia, prevalence ranged from as low as 0.3% in 
Hong Kong, Sendai, Japan and five major cities in mainland China(200) to as high as 
2.4% in the Philippines.(201)  
Map based on data from Refs(5),(202),(203),(204) 
 
 
Figure 3| Evidence of systemic inflammation in patients with psoriasis 
 
(A) Frontal reconstructions of 18-fludeoxyglucose (FDG) positron emission 
tomography (PET) – CT images of age, gender and body max index matched 
individuals  with (right) or without (left) psoriasis. High levels of tracer (FDG) 
uptake (darker areas) correspond to the presence of vascular (1), liver (2) skin (3) 
and joint (4) inflammation.  
 
(B) Transverse 18-FDG PET/CT images at the level of the aortic arch depict a higher 
tracer uptake in the aorta of a patient with psoriasis (left) compared with a healthy 
control (right), consistent with vascular inflammation.  
 
Image courtesy of Mehta Lab, NHLBI, NIH 
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Figure 4 Mechanisms of psoriasis.  
External insults such as trauma, infection or medication can cause the release of 
self-nucleotides, especially in genetically predisposed individuals. Self-nucleotides 
can form complexes with anti-microbial peptide (AMP) released from keratinocytes, 
for example cathelicidin (CAMP), which can bind to receptors on antigen presenting 
cells, including  toll-like receptor (TLR) -7 and -9 on the surface of plasmacytoid 
dendritic cells (pDCs). This binding triggers antigen presentation by pDCs, which 
prompt the activation and clonal expansion of antigen-specific CD8+ T cells. This 
process can occur in the dermis (activation of memory resident T cells) and local 
lymph nodes (activation of naive T cells). Subsequently, activated CD8 + T cells 
migrate into the epidermis where they encounter class I MHC receptors on the 
surface of keratinocytes (or perhaps melanocytes) and trigger the local release of 
soluble factors, including cytokines, chemokines, and innate immune mediators, 
which could further increase local inflammation and stimulate keratinocyte 
proliferation. pDCs release the inflammatory mediators interferon (IFN) –  and – , 
which stimulate myeloid dendritic cells (mDCs) to secrete additional pro-
inflammatory mediators such as IL-12, TNF and IL-23. These innate immunity 
mediators stimulate the activities of key T cell populations such as TH1, TH17 and 
TH22, which release additional cytokines and chemokines. IL-17 acts on 
keratinocytes (which express IL-17R) stimulating them to produce TNF, CCL20 
(chemotactic for T cells and DCs(205)). In combination with TNF and/or other pro-
inflammatory cytokines, IL-17 stimulates the production of defensins and 
chemokines, promoting host defence and leading to the recruitment of additional 
inflammatory cells into the lesion. IL-22 contributes to the characteristic psoriasis 
histologic phenotype, including epidermal hyperplasia, acanthosis and 
parakeratosis (incomplete keratinization with retention of nuclei). Key transcription 
factors in psoriasis include cAMP, the JAK-STAT family, and NF-κB; their activation 
leads to further production of factors such as TNF and interleukin-17 and 
downstream amplification loops.  
Expression of vascular endothelial growth factor receptors on endothelial cells 
induces vascular proliferation and expression of adhesion molecules within the 
endothelium to recruit additional inflammatory cells into the skin. Among other 
changes, these angiogenic factors lead to the characteristic tortuous (twitsting), 
papillary, dermal vessels of lesional psoriatic skin, which contribute to the 
development of Auspitz sign.  
A chronic phase is then established, which typically continues until a therapeutic 
intervention targeting key pathological regulators (for example, TNF or IL-17) 
breaks the cycle. However, after the withdrawal of treatment, a susceptible patient 
can relapse to the chronic phase with actively inflamed skin.  
 
Figure 5 Skin biopsy obtained from a patient with psoriasis vulgaris. Histological 
examination demonstrates acanthosis Munro microabscesses (an accumulation of 
neutrophils in the epidermis), alternating neutrophils, and parakeratosis in the 
stratum corneum, infiltration of mononuclear cells (for example, CD3+ T cells and 
CD11c+ dendritic cells) in the dermis and epidermis, tortuous dermal papillary 
vessels, increased mitotic activity of basal keratinocytes and abnormal keratinocyte 
marker expression.(75) 
 
Figure 6: Clinical markers of psoriasis.  (A) Koebner phenomenon occurs when a 
new area of psoriasis develops in injured skin. Psoriatic plaques seen in a 
distribution of skin damage secondary to a sunburn. (B) Nail pitting, the most 
common nail finding in psoriasis, occurs as depressions in the nail plate due to 
proximal nail matrix involvement. C. Psoriatic arthritis is an inflammation of the 
joints, which become sore and stiff. Dactylitis can also occur (swelling of the whole 
digit resulting from joint, tendon and soft tissue inflammation). 
 (D) Enthesitis showing an erosion and ǲfluffǳ at the insertion of the Achilles tendon 
into the calcaneous as well as a plantar spur. 
 
Table 1 | Biologic agents used in psoriasis. 
Drug Structure Mec
hani
sm 
of 
actio
n 
Indication* 
 
Effectivenes
s (PASI 75‡)  Standard dosing regimen  Reference  
Anti-TNF agents   
Etanercept Fustion 
protein 
between Fc 
portion of 
human IgG1 
fused and the 
extracellular 
domain of 
human p75 
TNF receptor  
TNF 
rece
ptor 
anta
goni
st 
Psoriasis 
and PsA 
  
49% at 
week 12 
Subcutaneous 
injections twice per 
week for 12 weeks, 
then once per week 
Refs. (206), 
(207) 
 
Adalimumab Human 
monoclonal 
antibody  
Anti 
TNF-Ƚ 
antib
ody 
Psoriasis 
and PsA 
 
53%  at 
week 12 
Subcutaneous 
injections; a 
loading dose first, 
then a regular dose 
regimen every 2 
weeks  
Refs. (208), 
(209) 
 
Infliximab Chimeric 
monoclonal 
antibody 
consisting of 
human IgG1 
with the 
mouse 
binding site 
for TNF-Ƚ 
Anti 
TNF-Ƚ 
antib
ody 
Psoriasis 
and PsA 
 
88% at 
week 10 
Intravenous 
infusion over 2 at 
weeks 0, 2 and, 6, 
then every 8 weeks 
Refs(210), 
(211),(212), 
(213) 
 
Certolizumab Pegylated 
humanized Anti PsA 
75% at 
week 12 
Subcutaneous 
injection; a loading 
Refs (214), 
(215) 
 
Fabǯ fragment  TNF-Ƚ 
antib
ody 
 dose first, then a 
regular dose  every 
2 weeks 
 
Golimumab Human 
monoclonal 
antibody  
Anti 
TNF-Ƚ 
antib
ody 
Psoriatic 
arthritis  
65% at 
week 52. 
Less 
effective 
against 
cutaneous 
psoriasis 
compared 
to the other 
biologic 
agents.  
Subcutaneous 
injection once 
every 4 weeks 
Ref (216)  
Others  
Ustekinumab 
 
Humanized 
monoclonal 
antibody 
directed 
against the 
p40 
component of 
IL-12 and IL-
23 
Anti 
IL-
12 
and 
anti 
IL-
23 
antib
ody 
Psoriasis 
and PsA 
 
67% and 
76% at 
week 12, 
patients 
weighing 
<100 kg 
and ≥ 100 
kg, 
respectively 
Subcutaneous 
injection at weeks 
0 and 4, then every 
12 weeks; weight-
based dosing (< or ≥100 kg) 
Ref (185)  
Secukinumab 
 
Human 
monoclonal 
antibody  
Anti 
IL-
17A 
antib
ody 
Psoriasis 
and PsA 
 
At week 12, 
PASI 75 
was 82%, 
PASI 90 
was 59% 
and PASI 
100 was 
29%  
Subcutaneous 
injections once a 
week for 5 weeks, 
then every 4 weeks 
Refs (217)  
Ixekizumab Humanized 
monoclonal 
antibody  
Anti 
IL-
17A 
antib
ody 
Psoriasis§; 
data for PsA 
are 
promising 
At week 12, 
PASI 75 
was 90%, 
PASI 90 
was 71% 
and PASI 
100 was 
41%  
Subcutaneous 
injections every 2 
weeks for 12 
weeks, then every 
4 weeks  
Ref (218)  
Brodalumab 
 
Humanized 
monoclonal 
antibody  
Anti 
IL-
17A 
rece
ptor 
antib
ody 
Approval for 
psoriasis 
pending; 
data for 
psoriatic 
arthritis are 
promising 
At week 12, 
PASI 75 
was 86.3%, 
PASI 90 
was 70.3% 
and PASI 90 
was 44.4%  
Subcutaneous 
injections at weeks 
0, 1 and 2, then 
every 2 weeks 
Ref (138)  
‡PASI 75 reflects the number of patients who have achieved >75% reduction in PASI scores in response to  
treatment. PsA, psoriatic arthritis; PASI, psoriasis area and severity index 
*In the United States, Canada and Europe 
§Approval pending in Canada 
 
  
Table 2 
 
Current clinical trials on biologics for psoriasis 
 
Therapeutic 
agent 
Mechanism of 
action Trialand status 
ClinicalTrials.gov 
identifier 
Tofacitinib  JAK 1 and JAK 3 
inhibition  
Randomized trial 
versus entanercept 
Completed 
NCT01241591 
 
Ruxolitinib 
(topical treatment) 
JAK 1 and JAK 3 
inhibition  
Randomized vehicle 
controlled safety and 
efficacy trial 
Completed 
NCT00820950 
 
Pazopanib VEGF antagonist  Randomized trial of 
efficacy  
Completed 
NCT00358384 
 
Ponesimod S1P1 receptor 
inhibition 
Randomized safety 
and efficacy trial 
Completed 
NCT01208090 
 
Guselkumab Il-23 inhibitor Randomized trial 
versus adalimumab 
Ongoing 
NCT02207244 
 
Tildrakizumab IL-23 inhibitor Randomized trial 
versus entanercept 
Ongoing 
NCT01729754 
 
Risankizumab 
 
IL-23 inhibitor Open label safety 
and efficacy trial 
Not yet recruiting 
NCT02772601 
 
IMO-8400 
 
TLR7, TLR8 and 
TLR9 inhibitor 
Randomized dose-
ranging trial 
Completed 
NCT01899729 
 
Namilumab 
 
GM-CSF receptor 
antagonist 
Randomized safety 
and efficacy trial 
Completed 
NCT02129777 
 
Piclidenoson 
(CF101) 
 
A3 adenosine 
receptor agonist  
Randomized safety 
and efficacy trial 
Completed 
NCT00428974 
 
Data from Ref. (184) 
JAK, Janus kinase, VEGF, vascular endothelial growth factor; S1P1, sphingosine 1-
phosphate receptor 1; TLR, toll-like receptor; GM-CSF Granulocyte macrophage colony 
stimulating factor 
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